Advertisement

Topics

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

00:08 EDT 29 Aug 2017 | Drugs.com

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation...

Original Article: FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer"

Quick Search
Advertisement